Marker Therapeutics (MRKR) Receives $13.1 Million Award to Support T-Cell Research – InvestorsObserver

Marker Therapeutics (MRKR) said Aug. 19 that it received a Product Development Research award totaling approximately $13.1 million from the Cancer Prevention and Research Institute of Texas (CPRIT). This award was given to support Marker Therapeutics Phase 2 clinical trial of MultiTAA-specific T cell product MT-401. The Phase 2 clinical trial of MT-401 is being studied a an adjuvant therapy to patient with acute myeloid leukemia (AML) following a hematopoietic stem cell transplant.

This is good news for the company a they progress with their study of MT-401. Peter L. Hoang, President & CEO of Marker Therapeutics, said in a press release, We are honored to have been approved by CPRIT for this award which provides additional capital to support the clinical development of MT-401 and external validation of our technology from experts in the field who conducted business and scientific diligence on behalf of CPRIT. Our MultiTAA-specific T cell therapy approach has shown encouraging results in post-transplant AML in clinical studies, and we are pleased to advance the clinical development of MT-401 in our Phase 2 trial."

MRKR has an Overall Score of 39. Find out what this means to you and get the rest of the rankings on MRKR!

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.

To see InvestorsObserver's full report on MRKR Click Here.

Excerpt from:

Marker Therapeutics (MRKR) Receives $13.1 Million Award to Support T-Cell Research - InvestorsObserver